Cyxone concludes T20K's preclinical program following positive results in toxicology studies
Cyxone (publ) announced today that the preclinical program for drug candidate T20K in multiple sclerosis (MS) has been concluded following positive results in the toxicology studies. The drug candidate T20K has now shown to be safe for people to ingest and the next step is to test the effect of T20K in clinical trials.The toxicology studies in the preclinical program were primarily intended to investigate the safety of taking the T20K substance, but also the dose to be administered to humans in clinical trials in a so-called dose escalation study. The studies were performed with the three